Artificial Intelligence in Drug Discovery: Transforming Pharmaceutical Research and Development
Year: 2026
Type: article
Abstract: Artificial Intelligence (AI) has emerged as a transformative force in drug discovery, addressing the limitations of traditional pharmaceutical research methods. Conventional drug development is a lengthy, costly, and high-risk process, often taking more than a decade with significant financial investment. AI technologies, including machine learning, deep learning, and data analytics, enable rapid processing of vast biological and chemical datasets, thereby accelerating the identification of potential drug candidates and improving decision-making throughout the discovery pipeline. AI applications span multiple stages of drug discovery, including target identification, virtual screening, lead optimization, and clinical trial design. By leveraging predictive models and pattern recognition, AI enhances the accuracy of molecular interactions, toxicity prediction, and pharmacokinetic profiling. Furthermore, AI-driven approaches facilitate drug repurposing, reducing development timelines and costs. The integration of AI with bioinformatics and cheminformatics has significantly improved efficiency, productivity, and success rates in pharmaceutical research. Despite its advantages, the implementation of AI in drug discovery faces challenges such as data quality issues, lack of interpretability, and regulatory concerns. However, ongoing advancements in computational power and algorithm development continue to overcome these limitations. AI is expected to play a pivotal role in the future of personalized medicine and precision therapeutics, ultimately revolutionizing the pharmaceutical industry and improving global healthcare outcomes.
Author: Rahul Sunil Padvi
Language: English
Subfield: Drug Discovery
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W7162094532
